Ropes & Gray has advised Mirador Therapeutics in its exclusive worldwide license agreement with Kira Pharmaceuticals. Mirador Therapeutics, Inc., a clinical-stage precision medicine company, has entered...
Mirador Therapeutics Secures Exclusive Worldwide License for Anti-C5a Antibody KP-301 from Kira Pharmaceuticals
Shionogi Acquires Global Rights to RADICAVA Business from Tanabe Pharma Corporation for $2.5 Billion
Cleary Gottlieb Steen & Hamilton LLP has advised Shionogi & Co. Ltd. and Shionogi Inc.; Ropes & Gray LLP has advised Tanabe Pharma Corporation. Shionogi &...
Bristol Myers Squibb and Bain Capital Establish Biopharmaceutical Company Focused on Immunology Therapies
Ropes & Gray has advised Bain Capital on the deal. Bristol Myers Squibb and Bain Capital have announced the creation of a new independent biopharmaceutical company...
AstraZeneca’s $160 Million Acquisition of FibroGen China
Ropes & Gray represented FibroGen, Inc. in the transaction. FibroGen, Inc. (NASDAQ: FGEN) announced the sale of its China subsidiary, Fibrogen China, to AstraZeneca for approximately...
Xerox Acquires Lexmark in $1.5 Billion Transaction
Ropes & Gray, Willkie, and Gibson Dunn have advised Xerox Holdings Corporation; Dechert has advised Lexmark International, Inc., and Ninestar Corporation, PAG Asia Capital, and Shanghai...
Zai Lab’s $200 Million Secondary Offering
Ropes & Gray represented Zai Lab Limited in the offering, while Simpson Thacher & Bartlett represented the underwriters. Zai Lab Limited (“Zai Lab” or the “Company”)...
Kailera Therapeutics’ $400 Million Series A Financing
Ropes & Gray advised Kailera Therapeutics, Inc. on the transaction. Kailera Therapeutics, Inc. (“Kailera”) announced raising $400 million in Series A financing. Kailera announced its launch...
Serán Bioscience’s $200 Million Growth Transaction
Ropes & Gray represented Bain Capital Life Sciences in the transaction. Serán Bioscience (“Serán”), a leading contract development and manufacturing organization (CDMO), announced a strategic growth...